Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $34.00.

A number of research analysts have recently weighed in on ARCT shares. Guggenheim downgraded shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 22nd. Citigroup reduced their price objective on Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday, January 6th. Wall Street Zen downgraded Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Piper Sandler dropped their price target on Arcturus Therapeutics from $140.00 to $72.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Finally, BTIG Research cut their price target on Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating for the company in a research note on Wednesday, October 22nd.

Hedge Funds Weigh In On Arcturus Therapeutics

Several large investors have recently modified their holdings of ARCT. AQR Capital Management LLC bought a new stake in shares of Arcturus Therapeutics in the first quarter valued at approximately $128,000. Millennium Management LLC bought a new position in Arcturus Therapeutics in the 1st quarter worth approximately $4,892,000. Goldman Sachs Group Inc. boosted its holdings in Arcturus Therapeutics by 9.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock worth $5,398,000 after buying an additional 42,636 shares during the period. Acadian Asset Management LLC purchased a new position in Arcturus Therapeutics in the 1st quarter valued at approximately $701,000. Finally, Strs Ohio bought a new stake in Arcturus Therapeutics during the 1st quarter valued at $89,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

NASDAQ ARCT opened at $7.37 on Thursday. The stock has a market capitalization of $209.38 million, a price-to-earnings ratio of -3.00 and a beta of 2.24. Arcturus Therapeutics has a one year low of $5.85 and a one year high of $24.17. The business’s fifty day moving average is $6.86 and its 200-day moving average is $12.46.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.60. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. The company had revenue of $17.15 million during the quarter, compared to analyst estimates of $17.47 million. Research analysts expect that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.